Conexeu Sciences Inc. (CNXU)
| Market Cap | 286.56M |
| Revenue (ttm) | n/a |
| Net Income | -5.35M |
| EPS | -0.35 |
| Shares Out | 25.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,403 |
| Open | 11.53 |
| Previous Close | 11.58 |
| Day's Range | 10.87 - 11.86 |
| 52-Week Range | 11.00 - 17.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CNXU
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tiss... [Read more]
Financial Performance
Financial StatementsNews
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leve...
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology Conexeu to leve...
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Public listing marks key milestone as Conexeu advances proprietary CXU(TM) platform and vision for regenerative medicine focused on biological restoration Reno, Nevada--(Newsfile Corp. - May 21, 2026)...
Conexeu Sciences opens at $13.50 after Nasdaq direct listing
Conexeu Sciences (CNXU), a preclinical developer of a regenerative tissue device for wound care and aesthetics, filed a resale prospectus with the SEC stating that it expects its common stock…